Moberg Pharma AB (OSTO:MOB) Net Income From Continuing Operations : kr-28.69 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Moberg Pharma AB's net income from continuing operations for the three months ended in Mar. 2024 was kr-7.90 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was kr-28.69 Mil.

Moberg Pharma AB Net Income From Continuing Operations Historical Data

The historical data trend for Moberg Pharma AB's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Net Income From Continuing Operations Chart

Moberg Pharma AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

64.82

-22.94

-20.12

-20.23

-27.46

Moberg Pharma AB Quarterly Data
	Mar19	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-6.67	-5.29	-7.26	-8.24	-7.90

Moberg Pharma AB Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-28.69 Mil.

Moberg Pharma AB (OSTO:MOB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

MOBs:UK MB8:Germany

Address

Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website

https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.